Actinium Pharmaceuticals, Inc. (ATNM)
EBITDA Growth
130.29%
TTM · Period ending:
ATNM EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported130.29%period ending
Latest reported130.29%period ending
ATNM TTM EBITDA YoY % (-30.53% → 130.29%)
Year-over-year change
High-resolution chart · PNG
ATNM ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 130.2852% | |
| 49.3749% | |
| 11.6638% | |
| 15.7795% | |
| 3.8212% | |
| 2.0076% | |
| 22.0621% | |
| 18.7896% | |
| 8.2232% | |
| -19.5018% | |
| -48.6107% | |
| -66.2649% | |
| -70.3911% | |
| -58.7766% | |
| -32.9849% | |
| -30.6059% | |
| -21.7981% | |
| -11.236% | |
| -10.7354% | |
| -12.9908% | |
| -3.7026% | |
| -0.0876% | |
| -1.5122% | |
| 14.2422% | |
| 8.3896% | |
| 6.2133% | |
| 9.0757% | |
| -3.7528% | |
| 0.0519% | |
| 9.3735% | |
| 11.4616% | |
| 20.156% | |
| 18.0849% | |
| 8.0674% | |
| -10.788% | |
| -17.5977% | |
| -31.6298% | |
| -24.0219% | |
| -15.6268% | |
| -13.1599% | |
| 8.4564% | |
| -78.9195% | |
| 19.6658% | |
| 15.2254% | |
| -14.4247% | |
| 53.4817% | |
| -142.335% | |
| -106.9475% | |
| -52.6622% | |
| -125.6055% | |
| 8.5682% | |
| -169.1991% | |
| -638.1531% | |
| -1,953.1096% | |
| -78,367.6037% | |
| -24,522.221% | |
| -14,131.2944% | |
| -4,866.9278% | |
| 81.4105% | |
| 170.0729% | |
| 162.7508% | |
| 165.3307% | |
| 152.1534% | |
| -81.52% | |
| -43.5409% | |
| 9.7433% | |
| 39.7971% | |
| 41.0113% | |
| 47.0768% | |
| 5.2079% | |
| -112.5764% | |
| -59.4285% | |
| -30.5301% |